Clinical trial
Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer
NCT00006228 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00006228 |
|---|---|
| Title | Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer |
| Official title | Phase II Trial of Anti-HER-2 Monoclonal Antibody Trastuzumab (Herceptin) in Combination With Low Dose Interleukin-2 (Proleukin) in Metastatic Breast Cancer Patients Who Have Previously Failed Trastuzumab |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer |
| Intervention type | Biological, Other |
| Interventions | trastuzumab, aldesleukin, laboratory biomarker analysis, pharmacological study |
| Enrollment | 37 |
| Start date | Jul 1, 2000 |
| Primary completion | Jul 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Oct 8, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: